The healthcare community is intrigued by retatrutide, a novel dual GIP and GLP-1 target that’s showing impressive results in preliminary trials . This compound works by mimicking natural hormones to affect appetite and boost feelings of fullness , ultimately resulting in considerable body loss . While currently under investigation and not broadly